BioDuro Partners with Silicogenix to Accelerate Complex Drug Discovery

• BioDuro has announced a collaboration with Silicogenix (SGX) to enhance early drug discovery using SGX’s fit-for-purpose small molecule design platform.

• The partnership aims to reduce costs and accelerate timelines for complex and rare disease therapies.

BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a partnership with Silicogenix (SGX) to enhance early-stage drug development. SGX is known for its proprietary small molecule design technology, which facilitates polypharmacology and non-traditional therapeutic approaches.

The partnership will integrate BioDuro’s drug discovery capabilities with SGX’s novel frameworks to help biopharma clients overcome cost and time challenges in developing complex and first-in-class therapeutics. The companies will jointly offer a streamlined path from discovery to preclinical development.

SGX’s technology provides access to much of the human proteome, enabling rapid iteration and testing of drug candidates, including potential combinations with existing standard-of-care therapies. This capability aligns with BioDuro’s commitment to delivering complex molecules at speed, aiming to support biopharma companies in bringing novel treatments to market efficiently.

“We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives,” said Dr. Subas Sakya, Chief Scientific Officer at BioDuro.

Dr. Shailesh Date, Co-founder of Silicogenix, added that the collaboration marks an important milestone for the biopharmaceutical sector. “This partnership represents real progress in how innovative treatments for complex and rare diseases can reach the market faster. With BioDuro’s leadership, we’re confident our combined approach will help biopharma companies significantly shorten development timelines and address critical unmet needs.”